Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Hirofumi Ohashi, Koichi Watashi, Tsukasa Yamamoto et al.|Antiviral Research|2022Cited by 33
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as TreatmentsDaisuke Akazawa, Koichi Watashi, Hirofumi Ohashi et al.|The Journal of Infectious Diseases|2023Cited by 30
Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus AgentsTakayuki Hishiki, Koichi Watashi, Takeshi Morita et al.|Microbiology Spectrum|2023Cited by 18
Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatmentsDaisuke Akazawa, Koichi Watashi, Hirofumi Ohashi et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 15
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Hirofumi Ohashi, Koichi Watashi, Takayuki Hishiki et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 6